Opendata, web and dolomites

MEXOM SIGNED

Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEXOM project word cloud

Explore the words cloud of the MEXOM project. It provides you a very rough idea of what is the project "MEXOM" about.

small    demonstrated    disability    preconditioning    private    effect    gmp    anti    mesenchymal    candidate    vitro    cargo    vesicles    clinically    receive    inflammation    mature    inflammatory    acute    entrepreneurship    micrornas    ex    societies    public    exert    medicine    immunomodulatory    he    host    innovations    skills    clinical    leader    preclinical    msc    failed    worldwide    communication    time    first    molecules    innovation    researcher    experiments    fellowship    academia    deleterious    manufacturing    quality    boosted    cells    vital    acquire    plays    stakeholders    assurance    vivo    advancing    career    world    medical    highlight    enrichment    models    transferable    treatment    grade    indicate    transfer    commercial    policymakers    unmet    regulations    extracellular    applicable    action    secreted    stem    industry    glp    training    mscs    intellectual    cell    property    molecular    ischemic    competences    cord    scientist    independent    regenerative    data    stroke    molecule    reinforce    human    biology    brain    civil    mechanism    evs   

Project "MEXOM" data sheet

The following table provides information about the project.

Coordinator
THE CELL-FACTORY 

Organization address
address: GALILEILAAN 19
city: NIEL
postcode: 2845
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-09-03   to  2020-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CELL-FACTORY BE (NIEL) coordinator 160˙800.00

Map

 Project objective

Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.

The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.

The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEXOM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEXOM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

BIOplasma (2019)

Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Read More  

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

ErgThComplexSys (2020)

Ergodic theory for complex systems: a rigorous study of dynamics on heterogeneous networks

Read More